Repligen Corporation Prices Public Offering of Shares of Common Stock
December 07 2020 - 9:40PM
Repligen Corporation (NASDAQ: RGEN) today announced the pricing of
an underwritten public offering of 1.5 million shares of its common
stock at a public offering price of $181 per share. In addition,
Repligen Corporation has granted the underwriters a 30-day option
to purchase up to an additional 225,000 shares of its common stock
at the public offering price, less underwriting discounts and
commissions. Repligen expects proceeds from the offering, before
deducting underwriting discounts and commissions and other offering
expenses, to be approximately $271.5 million, excluding any
exercise of the underwriters’ option to purchase additional shares.
The offering is expected to close on or about December 10, 2020
subject to customary closing conditions.Repligen Corporation
intends to use the net proceeds from this offering for working
capital and other general corporate purposes. Net proceeds from
this offering may also be used to fund possible acquisitions of, or
investments in, complementary businesses, products, services and
technologies. Repligen has not entered into any agreements or
commitments with respect to any acquisitions or investments at this
time.J.P. Morgan Securities LLC and Stifel, Nicolaus & Company,
Incorporated are acting as joint book-running managers for the
offering. Craig-Hallum Capital Group, Stephens Inc., SVB Leerink
LLC and William Blair & Company, L.L.C. are acting as
co-managers for the offering.These securities will be issued and
sold pursuant to an automatically effective shelf registration
statement (including a base prospectus) that was previously filed
with the Securities and Exchange Commission (“SEC”). A preliminary
prospectus supplement relating to this offering has been filed with
the SEC. Copies of the final prospectus supplement and the
accompanying prospectus relating to this offering, when available,
may be obtained from J.P. Morgan Securities LLC, Attention:
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, or by telephone at (866) 803-9204, or by email
at prospectus-eq_fi@jpmchase.com and from Stifel, Nicolaus
& Company, Incorporated, Attention: Syndicate, One Montgomery
Street, Suite 3700, San Francisco, California 94104, by telephone
at (415) 364-2720, or by email at syndprospectus@stifel.com.This
press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Repligen CorporationRepligen
Corporation is a global life sciences company that develops and
commercializes highly innovative bioprocessing technologies and
systems that increase efficiencies in the process of manufacturing
biological drugs. Our primary customers are biopharmaceutical drug
developers and contract development and manufacturing organizations
(CDMOs) worldwide. Our corporate headquarters are located in
Waltham, Massachusetts, with additional administrative and
manufacturing operations worldwide. The majority of our
manufacturing sites are located in the U.S. (California,
Massachusetts, New Jersey and New York), and outside of the U.S. we
have sites in Estonia, Germany, Ireland, the Netherlands and
Sweden.
Cautionary Language Concerning Forward-Looking
StatementsThis press release contains forward-looking
statements regarding our future business expectations, which are
subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that
statements in this press release which are not strictly historical
statements constitute forward-looking statements, including,
without limitation, statements regarding completion of the proposed
offering and the anticipated use of proceeds of the proposed
offering, constitute forward-looking statements identified by words
like “believe,” “expect,” “may,” “will,” “should,” “seek,”
“anticipate,” or “could” and similar expressions. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including, without limitation,
uncertainties related to market conditions and the completion of
the public offering on the anticipated terms or at all. These and
other risks and uncertainties are described in greater detail in
the section entitled “Risk Factors” in Repligen’s most recent
Annual Report on Form 10-K for the year ended December 31, 2019 and
in our Quarterly Report on Form 10-Q for the quarter ended March
31, 2020 on file with the Securities and Exchange Commission and
the other reports that Repligen periodically files with the
Securities and Exchange Commission. Actual results may differ
materially from those Repligen contemplated by these
forward-looking statements. These forward-looking statements
reflect management’s current views and Repligen does not undertake
to update any of these forward-looking statements to reflect a
change in its views or events or circumstances that occur after the
date hereof except as required by law.
Source:
Repligen CorporationSondra Newman Global Head of Investor
Relationssnewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024